EGFR and colorectal carcinoma: Current FDA‐approved molecularly targeted therapies for metastasized CRC include several monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor (EGFR), a multikinase small‐molecule inhibitor regorafenib, and a nucleoside analog trifluridine/tipiracil (Moriarity et al., 2016).